CUSUMIN Combination: A Cumulative Sum Interval Design for Phase I Cancer Drug-Combination Trials.
Tomoyoshi Hatayama1, Seiichi Yasui2
1Statistics and Decision Sciences Japan, Janssen Pharmaceutical K.K, Tokyo, Japan.
Pharmaceutical Statistics
|April 16, 2025
Summary
This study introduces CUSUMIN, a novel design for Phase I cancer trials that enhances safety in drug combination studies. CUSUMIN offers improved overdose control while maintaining maximum tolerated dose selection performance.
Area of Science:
- Oncology
- Biostatistics
- Clinical Trial Design
Background:
- Model-assisted designs like Bayesian Optimal Interval (BOIN) offer simplicity and good performance in Phase I cancer studies.
- Drug combinations are crucial in precision medicine but pose challenges for maximum tolerated dose (MTD) identification due to complex toxicity profiles.
- Existing model-assisted designs for drug combinations, such as BOIN and Keyboard, have similar operational characteristics and require further study.
Purpose of the Study:
- To develop a novel, simple, and high-performing design for Phase I cancer dose-combination studies.
- To improve upon existing model-assisted designs, specifically addressing overdose control and MTD selection in combination therapy trials.
- To extend the cumulative sum interval design (CUSUMIN) for single-agent studies to the complex setting of drug combinations.
Main Methods:
- Extension of the cumulative sum interval design (CUSUMIN) methodology, originally developed for single-agent dose-finding.
- Application of statistical quality control principles to enhance dose-finding algorithms.
- Comparison of CUSUMIN against existing model-assisted designs, including BOIN, for Phase I drug combination trials.
Main Results:
- The CUSUMIN design demonstrates superior performance in controlling overdosing rates compared to BOIN and other model-assisted designs.
- CUSUMIN maintains comparable performance in identifying the maximum tolerated dose (MTD) for drug combinations.
- The extended CUSUMIN design offers a safer patient allocation strategy in Phase I combination studies.
Conclusions:
- The CUSUMIN design provides a safer and effective alternative for Phase I cancer dose-combination studies.
- This novel approach enhances patient safety by reducing overdose rates while ensuring accurate MTD identification.
- CUSUMIN represents a significant advancement in model-assisted trial designs for combination therapies in oncology.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
10.8K
09:19Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
8.2K
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:21Cancer Survival Analysis
303
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
303
01:20Comparing the Survival Analysis of Two or More Groups
90
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
90
01:24Kaplan-Meier Approach
57
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
57
01:12Hazard Ratio
71
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
71
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
140
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
140